Nkarta Inc (NKTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cell Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 20.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.06% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Nkarta to Participate in September Investor Conferences
- Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
- Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
- Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
- Nkarta to Participate in Needham Virtual Healthcare Conference
- Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
- Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Nkarta Inc.
Full NKTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.